Beam Therapeutics receives FDA clearance for BEAM-304

• Beam Therapeutics (NASDAQ:BEAM) has received FDA clearance for its Investigational New Drug (IND) application for BEAM-304.
• The company is now positioned to initiate a Phase 1/2 clinical trial for patients with phenylketonuria (PKU).
• BEAM-304 utilizes an in vivo base-editing approach to correct PAH gene mutations and normalize plasma phenylalanine levels.

Beam Therapeutics (NASDAQ:BEAM) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BEAM-304.

The company is developing this candidate as an in vivo base-editing therapy designed to correct PAH gene mutations in patients with phenylketonuria.

The therapy employs lipid nanoparticle delivery to transport the editing components, which preclinical mouse data indicated could normalize plasma phenylalanine levels at clinically relevant doses.

Beam Therapeutics plans to begin a Phase 1/2 clinical trial to evaluate the safety and potential efficacy of the treatment in human PKU patients.

Following the announcement, the Beam Therapeutics share price was $24.15.

The company focuses on precision genetic medicines that use base editing to create durable treatments for serious genetic diseases.

This clearance adds to the firm's expanding clinical-stage pipeline, which includes other gene-editing candidates targeting various hematologic and metabolic conditions.